- Home
- TBI vs BDTX Comparison
TBI vs BDTX Comparison
Compare TBI & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TBI | BDTX |
|---|---|---|
| Founded | 1985 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.9M | 148.1M |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TBI | BDTX |
|---|---|---|
| Price | $5.54 | $2.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $6.00 | ★ $10.40 |
| AVG Volume (30 Days) | 183.4K | ★ 989.2K |
| Earning Date | 02-18-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.38 |
| Revenue | ★ $1,583,772,000.00 | $70,000,000.00 |
| Revenue This Year | $3.80 | N/A |
| Revenue Next Year | $5.04 | N/A |
| P/E Ratio | ★ N/A | $6.80 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.45 | $1.20 |
| 52 Week High | $8.55 | $4.94 |
Technical Indicators
Market Signals| Indicator | TBI | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 69.06 | 46.72 |
| Support Level | $4.92 | $2.36 |
| Resistance Level | $5.34 | $2.83 |
| Average True Range (ATR) | 0.28 | 0.16 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 97.06 | 55.77 |
Price Performance
Historical ComparisonAbout TBI TrueBlue Inc.
TrueBlue Inc is a provider of staffing and workforce management solutions. Its reportable segments include PeopleReady offers industrial staffing services. PeopleManagement offers contingent and productivity-based on-site industrial staffing services and PeopleScout offers recruitment process outsourcing, talent advisory services, and managed service provider services. It generates maximum revenue from the PeopleReady segment.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.